Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Huaier Granules for Bevacizumab- and Anlotinib-Related Proteinuria in Lung Cancer
NCT07358520Phase 4Not yet recruiting
- Sponsor
- Fudan University
- Start
- Jan 2026
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of huaier granule in proteinuria (2 arms), sponsored by Fudan University. Primary endpoint: Efficacy Rate for Proteinuria Treatment at 16 weeks. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
huaier granule
03
Conditions
proteinuria
Beyond the preview
Go deeper on NCT07358520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07358520.